What does a Fibrosis‑4 (FIB‑4) score of 3.37 indicate and how should it be managed?

FIB-4 Score of 3.37: High-Risk Advanced Fibrosis Requiring Immediate Action

A FIB-4 score of 3.37 indicates high-risk advanced liver fibrosis (above the 3.25 threshold) and requires immediate referral to hepatology or gastroenterology for further evaluation with elastography or liver biopsy, as this score is independently associated with increased risk of liver-related events, cardiovascular complications, and all-cause mortality.

What This Score Means

Your FIB-4 of 3.37 places you in the high-risk category for advanced fibrosis (bridging fibrosis or cirrhosis). The established cutoffs are 1, 2:

• Low risk: <1.3 (or <2.0 if age ≥65)
• Indeterminate: 1.3-3.25
• High risk: >3.25

At 3.37, you exceed the high-specificity threshold, meaning there is substantial concern for stage 3-4 fibrosis (bridging fibrosis to cirrhosis). Fibrosis stage is the strongest predictor of future liver-related outcomes including hepatocellular carcinoma, liver decompensation, transplantation, and death 2.

Critical Prognostic Implications

Beyond liver disease, your elevated FIB-4 carries serious extrahepatic risks:

• Mortality risk: A FIB-4 >3.25 is independently associated with 3.8-fold increased odds of postoperative mortality 3 and significantly elevated all-cause mortality in multiple disease contexts 4, 5
• Cardiovascular events: Elevated FIB-4 predicts myocardial injury (1.66-fold increased risk) and cardiovascular death 6, 3, 7
• Acute kidney injury: 1.5-fold increased perioperative risk 3
• Pulmonary complications: 1.3-fold increased postoperative risk 3

Immediate Management Algorithm

Step 1: Specialist Referral (Within 2-4 Weeks)

Refer to hepatology/gastroenterology for:

• Vibration-controlled transient elastography (VCTE/FibroScan) as the next step - this is the most widely available and validated imaging modality with excellent diagnostic accuracy (AUROC 0.87 for advanced fibrosis, 0.92 for cirrhosis) 1
• Alternative: Magnetic resonance elastography (MRE) if available, or Enhanced Liver Fibrosis (ELF) test if elastography unavailable 2
• Consider liver biopsy if elastography results are indeterminate or if specific histologic diagnosis needed 1

Step 2: Exclude Other Liver Disease Causes

Evaluate for:

• Viral hepatitis (HBV, HCV serology)
• Autoimmune hepatitis (ANA, ASMA, immunoglobulins)
• Hemochromatosis (iron studies, ferritin)
• Wilson disease if age <40 (ceruloplasmin, 24-hour urine copper)
• Alcohol use disorder (detailed history, consider AUDIT-C)
• Medication-induced liver injury (review all medications)

Step 3: Screen for Cirrhosis Complications (If Confirmed Advanced Fibrosis)

• Hepatocellular carcinoma surveillance: Ultrasound ± AFP every 6 months
• Esophageal varices screening: Upper endoscopy (EGD)
• Hepatic synthetic function: INR, albumin, bilirubin (calculate MELD score)
• Portal hypertension signs: Platelet count, splenomegaly on imaging

Step 4: Aggressive Metabolic Risk Factor Management

Given the strong association with metabolic dysfunction-associated steatotic liver disease (MASLD):

• Weight loss target: 7-10% body weight if overweight/obese
• Diabetes control: HbA1c <7% (consider GLP-1 agonists which may benefit liver disease)
• Cardiovascular risk reduction: Statin therapy, blood pressure control (<130/80 mmHg), antiplatelet therapy if indicated
• Avoid hepatotoxins: Alcohol abstinence, minimize acetaminophen, review all medications

Important Caveats

Age Considerations

The guidelines note that age affects FIB-4 accuracy, with higher cutoffs proposed for those ≥65 years (2.0 for ruling out advanced fibrosis) 1. However, recent data suggests that even in patients ≥65, a FIB-4 of 3.37 remains highly concerning and the standard 3.25 threshold should still prompt further evaluation 8. The meaning of elevated FIB-4 >2.67 is particularly strong in older adults and warrants direct action.

Limitations of FIB-4

• Modest positive predictive value (<70%): Not all patients with FIB-4 >3.25 have advanced fibrosis, hence the need for confirmatory testing 1
• False positives possible in NAFLD compared to viral hepatitis 1
• Sequential monitoring matters: Changes in FIB-4 over time refine risk - increasing scores worsen prognosis, decreasing scores improve it 4

Common Pitfalls to Avoid

1. Do not dismiss as "just fatty liver" - this score indicates potential advanced disease
2. Do not delay referral - liver-related mortality risk is significantly elevated
3. Do not ignore cardiovascular risk - these patients have multisystem disease requiring comprehensive management
4. Do not use FIB-4 alone for definitive diagnosis - it is a screening/triage tool requiring confirmation with elastography or biopsy 1, 2

The bottom line: A FIB-4 of 3.37 is a red flag requiring prompt hepatology evaluation with elastography to confirm fibrosis stage and initiate appropriate surveillance and treatment strategies to reduce liver-related and cardiovascular mortality risk.